AstraZeneca PLC (LON:AZN) Receives £104.12 Consensus Target Price from Brokerages

Shares of AstraZeneca PLC (LON:AZN) have been assigned an average rating of “Moderate Buy” from the nine analysts that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating on the company. The average 1-year price target among brokers that have covered the stock in the last year is £104.12 ($132.37).

A number of analysts have commented on the company. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a £110 ($139.84) target price on shares of AstraZeneca in a report on Tuesday, September 3rd. Berenberg Bank reiterated a “buy” rating and issued a £150 ($190.69) price objective on shares of AstraZeneca in a report on Monday, September 2nd. Shore Capital restated a “buy” rating on shares of AstraZeneca in a research note on Thursday, November 7th. Finally, JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a £140 ($177.98) price target on shares of AstraZeneca in a report on Friday, November 22nd.

Insider Buying and Selling at AstraZeneca

In other AstraZeneca news, insider Tony Mok acquired 1,500 shares of the business’s stock in a transaction dated Tuesday, November 19th. The stock was purchased at an average price of £126.80 ($161.20) per share, with a total value of £190,200 ($241,800.15). Also, insider Pascal Soriot acquired 20,000 shares of the business’s stock in a transaction dated Thursday, November 14th. The shares were acquired at an average cost of £102.03 ($129.71) per share, with a total value of £2,040,600 ($2,594,202.90). 0.04% of the stock is owned by corporate insiders.

AstraZeneca Price Performance

Shares of AZN opened at £104.02 ($132.24) on Wednesday. AstraZeneca has a twelve month low of GBX 9,461 ($120.28) and a twelve month high of £133.88 ($170.20). The company has a market capitalization of £161.23 billion, a P/E ratio of 3,335.24, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. The firm has a 50 day moving average of £109.27 and a 200 day moving average of £118.78. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 84.97.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.